Table 1 Demographic and clinical characteristics of patients with SSc enrolled in the study
Characteristic | Value |
|---|---|
Age (years), mean (SD) | 44.6 (15.4) |
Age (years), median (range) | 46.0 (20.0–67.0) |
Female, number (%) | 24 (85.7) |
Male, number (%) | 4 (14.3) |
Disease duration (months), mean (SD) | 44.7 (71.5) |
Disease duration (months), median (range) | 16.00 (3–360) |
Early disease, number (%) | 19 (67.9) |
Long-standing disease, number (%) | 9 (32.1) |
Anti-Scl-70 positivity, number (%) | 21 (75.0) |
ACA positivity, number (%) | 3 (10.7) |
RNA polymerase III positivity, number (%) | 1 (3.6) |
ANA positivitya, number (%) | 3 (10.7) |
dSSc, number (%) | 20 (71.4) |
lSSc, number (%) | 8 (28.6) |
Skin score, mean (SD) | 15.8 (11.3) |
Skin score, median (range) | 14.0 (2.0–43.0) |
Activity index, mean (SD) | 4.4 (2.0) |
Activity index, median (range) | 4.2 (1.0–8.5) |
Severity index, mean (SD) | 8.0 (2.6) |
Severity index, median (range) | 7.5 (4.0–14.0) |
FVC (%), mean (SD) | 87.8 ± 22.1 |
FVC (%), median (range) | 94.0 (41.0–123.0) |
DLCO (%), mean (SD) | 57.3 ± 18.4 |
DLCO (%), median (range) | 57.0 (26.0–93.0) |
HRCT interstitial score, mean (SD) | 7.6 (2.3) |
HRCT interstitial score, median (range) | 7.0 (4.0–14.0) |
HRCT alveolar score, mean (SD) | 6.7 (5.0) |
HRCT alveolar score, median (range) | 6.0 (0.0–16) |
ESR, mm/h, mean (SD) | 20.4 (20.3) |
ESR, median (range) | 12.0 (2.0–84.0) |